Beginning November 15, 2021, healthcare professionals prescribing clozapine, pharmacists and authorized representatives of pharmacies dispensing clozapine, and wholesalers/distributors distributing clozapine must recertify or reenroll in the Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program. All stakeholders may start to recertify and reenroll now.
The REMS administrator has changed, and the current “switch” pharmacy management system is being removed as a method to verify clozapine dispensing. Pharmacists will no longer use the switch system to obtain a pre-dispense authorization, now called a REMS dispense authorization (RDA). To obtain an RDA, visit the Clozapine REMS website or call the Clozapine REMS Contact Center at 888.586.0758.